JCI Insight (May 2021)

HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection

  • Yik Lim Kok,
  • Valentina Vongrad,
  • Sandra E. Chaudron,
  • Mohaned Shilaih,
  • Christine Leemann,
  • Kathrin Neumann,
  • Katharina Kusejko,
  • Francesca Di Giallonardo,
  • Herbert Kuster,
  • Dominique L. Braun,
  • Roger D. Kouyos,
  • Huldrych F. Günthard,
  • Karin J. Metzner

Journal volume & issue
Vol. 6, no. 9

Abstract

Read online

HIV-1 is capable of integrating its genome into that of its host cell. We examined the influence of the activation state of CD4+ T cells, the effect of antiretroviral therapy (ART), and the clinical stage of HIV-1 infection on HIV-1 integration site features and selection. HIV-1 integration sites were sequenced from longitudinally sampled resting and activated CD4+ T cells from 12 HIV-1–infected individuals. In total, 589 unique HIV-1 integration sites were analyzed: 147, 391, and 51 during primary, chronic, and late presentation of HIV-1 infection, respectively. As early as during primary HIV-1 infection and independent of the activation state of CD4+ T cells collected on and off ART, HIV-1 integration sites were preferentially detected in recurrent integration genes, genes associated with clonal expansion of latently HIV-1–infected CD4+ T cells, cancer-related genes, and highly expressed genes. The preference for cancer-related genes was more pronounced at late stages of HIV-1 infection. Host genomic features of HIV-1 integration site selection remained stable during HIV-1 infection in both resting and activated CD4+ T cells. In summary, characteristic HIV-1 integration site features are preestablished as early as during primary HIV-1 infection and are found in both resting and activated CD4+ T cells.

Keywords